Introduction
The development of obesity is influenced by various factors; however, in recent decades, researchers have been particularly intrigued by the role of gut microbiota. Specific changes in bacterial taxa and a decrease in diversity within the gut microbiota are observed among obese individuals (Hou et al., 2017). These changes contribute to an elevation in intestinal permeability and translocation of lipopolysaccharide (LPS) into blood circulation, leading to metabolic endotoxemia (Mohammad and Thiemermann, 2021). LPS has been proven to increase tight junction permeability by inducing enterocyte membrane expression and localization of Toll-like Receptor-4 (Guo et al., 2013). Obesity has been linked to elevated intestinal permeability. In genetically obese mice, there is an upregulation of intestinal permeability along with an increase in circulating endotoxins and pro-inflammatory cytokines such as interleukin one beta (IL-1β), interleukin-6 (IL-6), interferon-gamma (INFγ), and tumor necrosis factor (TNF-α), when compared to wild-type mice (Lee et al., 2018). Conversely, obesity induced by a high-fat diet, also known as diet-induced obesity (DIO), is associated with alterations in the gut microbial population that are associated with inflammation and heightened intestinal permeability, likely due to diminished expression of tight junction (TJ)-related genes, including ZO-1 and occludin. These collective observations indicate that obesity-related inflammation may be linked to disruptions in the integrity of TJ structures and alterations in the composition of the intestinal microbiota (Aleman et al., 2023).
Obese individuals have shown higher serum LPS concentrations along with TNF-α and IL-6. Among Mexican obese subjects, a positive correlation has been found between serum LPS and BMI, triglyceride, and waist circumference (Radilla-Vázquez et al., 2016). Thus, the assessment of serum endotoxin concentrations along with cytokines profile indicates the degree of systemic inflammation in obese individuals. Subsequently, several clinical trials have attempted to examine the effect of the administration of prebiotics and probiotics (synbiotics) simultaneously on ameliorating metabolic endotoxemia (Fernandes et al., 2017). Serum LPS or LPS binding protein (LPB) concentrations were the main outcomes measured in those trials. Measuring LPS levels before and after interventions can provide insights into the effectiveness of synbiotics in reducing inflammation and improving gut health.
Discussion
Recently, Krumbeck et al. (2018) examined the effect of specific strains (B.adolescentis and B.animals) of Bifidobacterium along with galactooligosaccharides on intestinal permeability and endotoxemia among obese individuals. Metabolic markers, intestinal permeability, and endotoxin concentrations were measured in the study. This synbiotic treatment, composed of Bifidobacterium and galactooligsacchrides, enhanced the colonic permeability. During the study period, serum endotoxin was measured thrice. The authors concluded that no statistical significance was found in serum LPS and LBP among all the groups. However, the main drawback of the study is that the serum values of LPS and LBP were not presented either in the main manuscript or in the additional files section. It is unknown whether the baseline values of LPS and LBP are at high or low concentrations. Therefore, comparing the results of LPS and LBP with other clinical trials that used galactooligosaccharides or Bifidobacterium could not be applicable. Moreover, Krumbeck et al. (2018) did not consider measuring serum cytokines in the studied subjects. On the other hand, galactooligosaccharide supplementation led to a significant reduction in plasma LPS and C-reactive protein among obese individuals after 14 days of consumption (Morel et al., 2015). In addition, overweight and obese females who consumed Bifidobacterium for 8 weeks had lower levels of serum endotoxin compared with the control group (Gomes et al., 2017). Furthermore, compelling evidence suggests that prebiotics possess the capacity to bind with LPS within the intestinal lumen, effectively suppressing the translocation of LPS into the bloodstream (Snelson et al., 2021). Certain probiotic strains, particularly those belonging to the Lactobacillus and Bifidobacterium genera, assist in restoring the integrity of the gut barrier and reduce intestinal permeability. By enhancing the production of tight junction proteins, probiotics can strengthen the barrier function of the intestinal lining, thereby limiting the translocation of LPS from the gut lumen into the blood circulation (Han et al., 2016).
Conclusion
In conclusion, the endotoxin findings by Krumbeck and her colleagues (2018) should be published in a specific corrigendum to illustrate the serum values of LPS and LBP. However, we suggest a deep discussion on the ineffectiveness of galactooligosaccharide over serum endotoxin levels and other inflammatory cytokines. Overall, this study is groundbreaking but further trials and testing are indispensable.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AlemanR. S.MoncadaM.AryanaK. J. (2023). Leaky gut and the ingredients that help treat it: A review. Molecules28, 619. 10.3390/molecules28020619
2
FernandesR.do RosarioV. A.MocellinM. C.KuntzM. G. F.TrindadeE. B. S. M. (2017). Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: A systematic review. Clin. Nutr.36, 1197–1206. 10.1016/j.clnu.2016.10.003
3
GomesA. C.de SousaR. G. M.BotelhoP. B.GomesT. L. N.PradaP. O.MotaJ. F. (2017). The additional effects of a probiotic mix on abdominal adiposity and antioxidant status: A double-blind, randomized trial. Obesity25, 30–38. 10.1002/oby.21671
4
GuoS.Al-SadiR.SaidH. M.MaT. Y. (2013). Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am. J. Pathol.182, 375–387. 10.1016/j.ajpath.2012.10.014
5
HanC.DingZ.ShiH.QianW.HouX.LinR. (2016). The role of probiotics in lipopolysaccharide-induced autophagy in intestinal epithelial cells. Cell. Physiol. biochem.38, 2464–2478. 10.1159/000445597
6
HouY. P.HeQ. Q.OuyangH. M.PengH. S.WangQ.LiJ.et al (2017). Human gut microbiota associated with obesity in Chinese children and adolescents. Biomed. Res. Int.2017, 7585989. 10.1155/2017/7585989
7
KrumbeckJ. A.RasmussenH. E.HutkinsR. W.ClarkeJ.ShawronK.KeshavarzianA.et al (2018). Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome6, 121. 10.1186/s40168-018-0494-4
8
LeeJ. Y.WasingerV. C.YauY. Y.ChuangE.YajnikV.LeongR. W. L. (2018). Molecular pathophysiology of epithelial barrier dysfunction in inflammatory bowel diseases. Proteomes6, 17. 10.3390/PROTEOMES6020017
9
MohammadS.ThiemermannC. (2021). Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front. Immunol.11, 594150. 10.3389/fimmu.2020.594150
10
MorelF. B.DaiQ.NiJ.ThomasD.ParnetP.Fança-BerthonP. (2015). α-Galacto-oligosaccharides dose-dependently reduce appetite and decrease inflammation in overweight adults. J. Nutr.145, 2052–2059. 10.3945/jn.114.204909
11
Radilla-VázquezR. B.Parra-RojasI.Martínez-HernándezN. E.Márquez-SandovalY. F.Illades-AguiarB.Castro-AlarcónN. (2016). Gut microbiota and metabolic endotoxemia in young obese mexican subjects. Obes. Facts9, 1–11. 10.1159/000442479
12
SnelsonM.de PasqualeC.EkinciE. I.CoughlanM. T. (2021). Gut microbiome, prebiotics, intestinal permeability and diabetes complications. Best. Pract. Res. Clin. Endocrinol. Metab.35, 101507. 10.1016/j.beem.2021.101507
Summary
Keywords
lipopolysaccharide, serum, Bifidobacterium, lipopolysaccharide binding protein, obesity
Citation
Ranneh Y, Mahmoud AM, Fadel A, Abu Bakar MF and Md Akim A (2023) Comments on “Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics”. Front. Pharmacol. 14:1228359. doi: 10.3389/fphar.2023.1228359
Received
24 May 2023
Accepted
03 August 2023
Published
17 August 2023
Volume
14 - 2023
Edited by
Carolina Pellegrini, University of Pisa, Italy
Reviewed by
Clelia Di Salvo, University of Pisa, Italy
Cinzia Parolini, University of Milan, Italy
Updates
Copyright
© 2023 Ranneh, Mahmoud, Fadel, Abu Bakar and Md Akim.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yazan Ranneh, yazan.ranneh@aau.ac.ae
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.